Ex,
What you're saying would be true of most biotech's I know, but NWBO is unlike any other biotech I've ever followed, and given what we know from Dr. Liau's 2018 SNO presentation, it's likely to be the most successful biotech I know of, with the possible exception of AMGN.
My biggest biotech mistake was not investing in AMGN in the early 1990's at roughly $15 when I first heard about it. By the end of the decade it was selling for nearly $100, which sounds good, but not great, but during that time it had multiple splits which totaled 48 to 1 during that decade. If in this decade NWBO remains independent and both DCVax's are approved for multiple solid cancers by the end of the decade, I'm not certain it couldn't be as big as AMGN back in it's decade, but because of the current share count, it certainly won't split anywhere near 48 to 1, but perhaps a split might be possible before the end of the decade to avoid the share price reaching four digits, which would be rather pricy.
I'm not suggesting that the DCVax's cure cancers as a monotherapy, but I believe that they'll be shown to make many therapeutics work better, and in many cases it will result in a cure, where without it life may very well be extended, but a cure won't necessarily be achieved.
It's been many years since my initial investment in IMGN. At the time I believe conjugates were an elegant way of approaching cancer. I still believe that they have their place and that IMGN has a few that are approaching approval. I currently hold about half the share I held when I had the greatest number of shares, and far more than I've had in more recent years. I do believe that like NWBO, IMGN will have approvals next year with more information on it's drugs due in conferences later this year. I own substantially more of NWBO than that, but I still believe my holdings in IMGN could be significant in the next few years, significant being 6 digit or more. I believe I could easily be into 7 digits with NWBO by late this year, or early next, time will tell.
Gary
